Goodwin Procter·PHARMA / BIOTECH
Celltrion Debuts OMLYCLO, First FDA‑Approved Interchangeable Biosimilar
On Oct 5, 2026, Celltrion’s OMLYCLO becomes the first interchangeable biosimilar to XOLAIR, marking a significant regulatory milestone in allergy therapeutics.
celltrionomalizumabbiosimilarxolafda‑approval
Read the original firm alert → Friday, October 16, 2026